We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

130 hedge funds and large institutions have $196M invested in Lumos Pharma, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $6.83M | Put options by funds: $3.24M

65% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 26

24% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 25

3% more funds holding

Funds holding: 126 → 130 (+4)

1% less capital invested

Capital invested by funds: $199M → $196M (-$2.52M)

Holders
130
Holders Change
+4
Holders Change %
+3.17%
% of All Funds
2.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
43
Reduced
26
Closed
25
Calls
$6.83M
Puts
$3.24M
Net Calls
+$3.59M
Net Calls Change
-$6.72M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$18.3M
2
Millennium Management
Millennium Management
New York
+$9.64M
3
RG
Redmile Group
California
+$7.79M
4
ACA
Avoro Capital Advisors
New York
+$7.31M
5
BlackRock
BlackRock
New York
+$3.73M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.46M
2
CCI
Columbus Circle Investors
-$4.95M
3
MWNA
Marshall Wace North America
New York
-$3.88M
4
PP
PDT Partners
New York
-$3.56M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
101
JP Morgan Chase
New York
$58K +$60K +725 +1,007%
EP
102
Elkfork Partners
Oregon
$48K -$39.2K -474 -42%
BNP Paribas Financial Markets
103
BNP Paribas Financial Markets
France
$47.6K +$34.7K +419 +180%
Parallax Volatility Advisers
104
Parallax Volatility Advisers
California
$36K +$40.9K +495 New
TAM
105
Tyers Asset Management
Texas
$35K -$28.5K -345 -42%
UBS Group
106
UBS Group
Switzerland
$33K +$7.86K +95 +26%
US Bancorp
107
US Bancorp
Minnesota
$26K – – –
FGC
108
Financial Gravity Companies
Texas
$18K +$20.2K +244 New
Canada Life
109
Canada Life
Manitoba, Canada
$17K – – –
NIT
110
NumerixS Investment Technologies
British Columbia, Canada
$14K +$15.6K +189 New
AIP
111
Ameritas Investment Partners
Nebraska
$13K – – –
MA
112
MCF Advisors
Kentucky
$13K – – –
NSIM
113
North Star Investment Management
Illinois
$9K – – –
Royal Bank of Canada
114
Royal Bank of Canada
Ontario, Canada
$8K -$16.2K -196 -63%
Fifth Third Bancorp
115
Fifth Third Bancorp
Ohio
$8K – – –
CHP
116
Cable Hill Partners
Oregon
$5K – – –
LTFS
117
Ladenburg Thalmann Financial Services
Florida
$5K – – –
FANJ
118
Financial Architects (New Jersey)
New Jersey
$5K +$2.32K +28 +72%
KF
119
Krilogy Financial
Missouri
$4K – – –
SO
120
STRS Ohio
Ohio
$4K – – –
IA
121
IFP Advisors
Florida
$4K +$4.63K +56 New
Northwestern Mutual Wealth Management
122
Northwestern Mutual Wealth Management
Wisconsin
$3K – – –
Citigroup
123
Citigroup
New York
$2K -$19.9K -241 -90%
AIM
124
Advantage Investment Management
Iowa
$2K – – –
CIBC Private Wealth Group
125
CIBC Private Wealth Group
Georgia
$2K +$1.82K +22 New
3 4
5
6 7

LUMO Hedge Fund Activity: Q4 2017 in Review

130 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2017, worth a combined $196M — down 1.3% from $199M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new LUMO positions and 25 closed out — a net gain of 6 holders — while 43 added to existing stakes and 26 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $18.3M. The largest seller was OrbiMed, exiting entirely with an estimated $8.46M sold.

  • 130 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2017, up from 126 in Q3 2017.
  • Funds reported $196M of Lumos Pharma, Inc. Common Stock stock for Q4 2017, down 1.3% quarter-over-quarter.
  • 31 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2017 and 25 closed out, a net change of +6 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2017 was Great Point Partners, an estimated $18.3M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2017 was OrbiMed, an estimated $8.46M sold.

Based on aggregated 13F filings for Q4 2017.